David H. Altreuter

TL;DR: In this article, low aqueous solubility drugs are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aaqueous media.

TL;DR: The use of synthetic, biodegradable nanoparticles carrying either protein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durable and antigen-specific immune tolerance, even in the presence of potent Toll-like receptor agonists is described.

TL;DR: It is demonstrated that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying rapamycin, but not free rapamyzin, are capable of inducing durable immunological tolerance to co-administered proteins that is characterized by the induction of tolerogenic dendritic cells, an increase in regulatory T cells, a reduction in B cell activation and germinal centre formation, and the inhibition of antigen-specific hypersensitivity reactions.

TL;DR: In this article, a synthetic vaccine particle (SVPP) technology was developed to enable co-encapsulation of antigen with potent adjuvants and demonstrated that co-delivery of an antigen with a TLR7/8 or TLR9 agonist in synthetic polymer nanoparticles results in an augmentation of humoral and cellular immune responses with minimal systemic production of inflammatory cytokines.

TL;DR: In this article, a single-step spray drying and in-line jet milling process was proposed to deal with the problem of particle deagglomeration and grinding in a single unit operation.